ALCLS Cellectis S.A.
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.…
Industry Peers
BiotechnologyKey Statistics
About Cellectis (EPA: ALCLS)
›
Cellectis (EPA: ALCLS) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 224 employees.
The shares were at 0.9710 EUR on 19 November 2026, down 77.4% over 52 weeks. Its 52-week range is 0.8950 EUR to 4.750 EUR: the price is 79.6% below the high and 8.5% above the low.
Its market capitalisation is 98.72M EUR.
Cellectis reports return on equity of -89.1%, an operating margin of -384.9% and revenue down 85.4% year over year.
It holds more cash than debt, a net cash position of 120.82M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 18 March 2027.